Zacks Investment Research · May 4, 2023
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.
JN
NASDAQ · JNCE
Jounce Therapeutics, Inc.
Healthcare · Biotechnology
$1.88
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 10:32 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 98.95M
- P/E ratio
- -1.91
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 11.6M
- Avg. volume
- 3.47M
Price performance
JNCE price history
1M range · 0 trading sessions · Daily adjusted prices
JNCE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest JNCE news
The latest Smart Investors Daily articles mentioning JNCE.
Stock researchCompany · Overview
JNCE research
Overview
Company profile and research snapshot.
Company profile
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 24, 2023 | SMBC Nikko | Neutral | — |
| Feb 23, 2023 | Raymond James | Market Perform | — |
| Jan 3, 2023 | Piper Sandler | Overweight | — |
| Nov 11, 2022 | Raymond James | Outperform | — |
| Aug 31, 2022 | Raymond James | Strong Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · May 4, 2023
Jounce Therapeutics Announces Closing of Tender Offer
Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights
Zacks Investment Research · Apr 11, 2023
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
GlobeNewswire Inc. · Apr 3, 2023
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
